减肥药双雄争霸：诺和诺德惨败礼来，股价一夜崩盘！

Core Viewpoint - The competitive landscape of the weight loss drug market has shifted dramatically, with Novo Nordisk facing a significant decline due to its new drug underperforming compared to Eli Lilly's offering, leading to a historic stock drop for Novo Nordisk [1][2][6]. Group 1: Novo Nordisk's Performance - Novo Nordisk's stock plummeted over 16%, reaching its lowest point since June 2021, with a market capitalization reduced to $176.948 billion [2]. - The company's drug CagriSema resulted in a weight loss of 20.2% after 84 weeks of treatment, which is lower than Eli Lilly's Tirzepatide, which achieved a 23.6% weight loss [7][8]. - Novo Nordisk's CEO expressed optimism about CagriSema despite the disappointing trial results, and the company is exploring higher dosage combinations for further testing [10][11]. Group 2: Eli Lilly's Growth - Eli Lilly's stock rose by 4.8%, with a total market capitalization of $998.6 billion, driven by the success of its weight loss drug Zepbound [2]. - Zepbound's revenue in the fourth quarter reached $4.2 billion in the U.S., a 122% increase year-over-year, indicating explosive demand since its launch [16]. - Eli Lilly's Tirzepatide generated $36.5 billion in revenue in 2025, surpassing Novo Nordisk's Ozempic and Wegovy, with significant growth in both diabetes and weight loss segments [18]. Group 3: Market Outlook - Analysts predict that Eli Lilly's Zepbound will continue to dominate the market, with expectations of sustained growth beyond 2026 [19]. - The introduction of Eli Lilly's next-generation drug, retatrutide, is likely to further challenge Novo Nordisk's market position [20]. - The competitive pressure on Novo Nordisk is expected to remain high, as Eli Lilly consistently withstands any challenges posed by Novo Nordisk [21].